- Home
- OR vs MIRM Comparison
OR vs MIRM Comparison
Compare OR & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OR | MIRM |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 7.2B |
| IPO Year | 2014 | 2019 |
Fundamental Metrics
Financial Performance| Metric | OR | MIRM |
|---|---|---|
| Price | $34.63 | $80.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 14 |
| Target Price | $43.00 | ★ $145.79 |
| AVG Volume (30 Days) | 626.1K | ★ 632.1K |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,138,000.00 |
| Revenue This Year | $39.38 | $33.62 |
| Revenue Next Year | $11.83 | $17.65 |
| P/E Ratio | $55.77 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.54 | $63.23 |
| 52 Week High | $48.06 | $130.00 |
Technical Indicators
Market Signals| Indicator | OR | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 44.79 | 23.27 |
| Support Level | $32.35 | $73.82 |
| Resistance Level | $37.87 | $104.56 |
| Average True Range (ATR) | 0.93 | 3.73 |
| MACD | -0.32 | -0.96 |
| Stochastic Oscillator | 17.01 | 8.81 |
Price Performance
Historical ComparisonAbout OR Osisko Gold Royalties Ltd
OR Royalties Inc is engaged in the business of acquiring and managing precious metal and other high-quality royalties, streams and similar interests. The Company owns a portfolio of royalties, streams, offtakes, options on royalty/stream financings and exclusive rights to participate in future royalty/stream financings on various projects. Geographically, it generates majority of its income from North America and also generates some portions of income from South America, Australia, Africa and Europe.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.